GlassScriptPhysician profile
Douglas W Jacobson
NPI 1316058639
$3,365.63
in general payments reported to CMS, 2019-2025
16 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $275 · 2021: $49.82 · 2022: $378 · 2023: $848 · 2024: $221 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $933.98 | 2019-2023 | Catalys System |
| Alcon Vision LLC | $775.62 | 2019-2025 | Centurion, Clareon, Argos |
| Sight Sciences, INC. | $411.30 | 2020-2023 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $222.47 | 2019 | |
| Abbvie INC. | $170.98 | 2022-2023 | |
| Ivantis, INC | $133.90 | 2019 | |
| Biogen, INC. | $130.24 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $111.58 | 2019 | |
| Bausch & Lomb Americas INC. | $104.17 | 2024 | Miebo, Xiidra |
| Apellis Pharmaceuticals, INC. | $103.27 | 2023 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $98.94 | 2023 | Eylea |
| Pharmacyclics LLC, An Abbvie Company | $60.42 | 2019 | |
| Nova Eye, INC. | $37.33 | 2024 | |
| Optos, INC. | $35.73 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $16.30 | 2024 | Forum |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.